Updated Covid Vaccines Cut Veteran Hospitalizations Forty-Four Percent
Two studies of more than 1 million U.S. veterans found the 2025-26 COVID vaccine was associated with 43.6 percent fewer hospitalizations over 180 days, and Moderna's newer vaccine outperformed Pfizer's among veterans 65 and older.
Edited and fact-checked by Stephen Sprague
The next seasonal vaccine round will be chosen with a head-to-head veteran comparison on the table for the first time.
Veterans who took both shots on the same day last season show up in the data with fewer emergency visits and fewer hospital stays. Two studies published this week put numbers on that pattern across more than 1 million people, and both are observational, so they record associations inside VA records rather than the controlled proof a randomized trial would give.
The VA Saint Louis Health Care System team, publishing in Vaccine, followed 931,943 veterans who received a flu vaccine between September 21, 2025, and January 31, 2026. A total of 114,911 of them took a COVID vaccine on the same day, and 817,032 received the flu vaccine alone, which gave the researchers a comparison group drawn from the same clinics and the same season.
Across the 180 days that followed, COVID vaccination was associated with a 31.7 percent reduction in COVID-related emergency department visits and a 43.6 percent decrease in hospitalizations. The absolute terms are smaller and the authors state them openly, at about seven fewer emergency visits and roughly three fewer hospitalizations for every 10,000 people vaccinated.
A second team at the VA Providence Healthcare System, publishing in JAMA Network Open, compared the two mRNA products head to head among 294,499 veterans aged 65 and older. Medically attended COVID occurred in 86 of 55,349 recipients of Moderna's mRNA-1283 vaccine, 0.16 percent, against 672 of 239,150 Pfizer recipients, 0.28 percent, which works out to 35.9 percent greater relative effectiveness for the Moderna shot.
Hospitalizations separated the products by a wider relative margin, with 11 cases among Moderna recipients, 0.02 percent, and 114 among Pfizer recipients, 0.05 percent, a 47.0 percent greater relative effectiveness. In absolute terms the comparison is about 10 fewer medically attended cases and two fewer hospitalizations per 10,000 vaccinated people, and the Providence team wrote that the result could inform seasonal vaccine selection for older adults at high risk.
Neither study can separate the vaccine's effect from the habits of the veterans who chose it, and that limit sits inside both papers rather than in a footnote. The Saint Louis authors framed their contribution in practical terms, writing that the findings quantify the benefit of vaccination in a lower-incidence season and can inform shared clinical decision making and seasonal vaccine policy.
The conversation.
Loading comments…
A little more perspective.
Reading is free. Verified members can comment and reply for $2 a month.